IMVT Immunovant Inc

Price (delayed)

$8.49

Market cap

$976.34M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.16

Enterprise value

$600.39M

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous ...

Highlights
Immunovant's debt has decreased by 25% YoY and by 11% QoQ
Immunovant's EPS has increased by 18% YoY and by 4.9% QoQ
The equity has grown by 37% YoY but it has contracted by 7% from the previous quarter
IMVT's quick ratio is up by 29% year-on-year but it is down by 13% since the previous quarter
IMVT's net income has plunged by 52% YoY and by 3.5% from the previous quarter

Key stats

What are the main financial stats of IMVT
Market
Shares outstanding
115M
Market cap
$976.34M
Enterprise value
$600.39M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.28
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$111.64M
EBITDA
-$110.51M
Free cash flow
-$90.92M
Per share
EPS
-$1.16
Free cash flow per share
-$0.93
Book value per share
$3.73
Revenue per share
$0
TBVPS
$3.96
Balance sheet
Total assets
$388.03M
Total liabilities
$22.5M
Debt
$3.06M
Equity
$365.53M
Working capital
$364.3M
Liquidity
Debt to equity
0.01
Current ratio
18.75
Quick ratio
18.47
Net debt/EBITDA
3.4
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-26.4%
Return on equity
-27.6%
Return on invested capital
N/A
Return on capital employed
-30.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IMVT stock price

How has the Immunovant stock price performed over time
Intraday
-0.47%
1 week
-5.25%
1 month
13.2%
1 year
-78.17%
YTD
-81.62%
QTD
-19.68%

Financial performance

How have Immunovant's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$111.42M
Net income
-$111.19M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 53% year-on-year and by 3.1% since the previous quarter
IMVT's net income has plunged by 52% YoY and by 3.5% from the previous quarter

Growth

What is Immunovant's growth rate over time

Valuation

What is Immunovant stock price valuation
P/E
N/A
P/B
2.28
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Immunovant's EPS has increased by 18% YoY and by 4.9% QoQ
The stock's price to book (P/B) is 63% less than its last 4 quarters average of 6.1
The equity has grown by 37% YoY but it has contracted by 7% from the previous quarter

Efficiency

How efficient is Immunovant business performance
IMVT's return on equity has surged by 55% year-on-year and by 2.8% since the previous quarter
IMVT's return on assets is up by 42% year-on-year and by 2.2% since the previous quarter

Dividends

What is IMVT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMVT.

Financial health

How did Immunovant financials performed over time
IMVT's total assets is up by 34% YoY but it is down by 6% QoQ
IMVT's quick ratio is up by 29% year-on-year but it is down by 13% since the previous quarter
Immunovant's debt is 99% lower than its equity
The debt to equity has dropped by 50% year-on-year
The equity has grown by 37% YoY but it has contracted by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.